FIG. 4.

Longitudinal changes in patients exhibiting high and low levels of monocyte uPAR expression. Representative placebo-treated patients (A) grouped by high baseline levels of uPAR and low baseline levels of uPAR are compared to glatiramer acetate-treated patients (B) grouped according to high baseline levels and low baseline levels. Glatiramer acetate-treated patients who started the trial with low baseline uPAR values exhibited less overall fluctuation in uPAR expression and lower mean levels than treated patients with high levels at the start of the trial and than placebo patients.